ReviewVaccines2021
Commercial PRRS Modified-Live Virus Vaccines.
Review in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 102 citations in OpenAlex.
- Growth performance and immune responses of pigs from nursery to grower-finisher phase following different PRRSV-2 vaccination strategies: Evidence supporting a prime-boost regimen under field conditions in Korea.Canadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2026Article
- Evaluation of the contribution of the minor envelope complex glycoprotein 3 ectodomain to the porcine reproductive and respiratory syndrome virus 1 neutralizing antibody response.The Journal of general virology · 2026Article
- A Lipid Nanoparticle-Formulated GP5-mRNA Vaccine Induces PRRSV-Specific Humoral and Cellular Immune Responses in BALB/c Mice.Veterinary sciences · 2026Article
- Integrated Single-Cell and TCR Profiling Reveals Protection-Associated CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Geographic Distribution and ORF5 Diversity of PRRSV-2 Variants in Midwestern U.S. Diagnostic Submissions, 2023-2025.Pathogens (Basel, Switzerland) · 2026Article
- CRISPR mediated PRRS resistant pigs: biological success, welfare implications, and ethical regulatory challenges for sustainable swine production.Porcine health management · 2026Review
- Genetic Characterization of PRRSV Diversity and Detection of Other Pathogens in Live Virus Inoculation Material Used in Breeding Herd Stabilization Programs.Microorganisms · 2026Article
- STING agonists as antiviral agents.FEBS letters · 2026Review
- Serological Findings in Pigs Vaccinated AgainstVeterinary sciences · 2026Article
- Early Detection of Porcine Reproductive and Respiratory Syndrome Virus Outbreak: Combination of Methods.Veterinary sciences · 2025Article
- Article
- Genetic Diversity and Temporal Shifts of Porcine Reproductive and Respiratory Syndrome Virus Type 2 (PRRSV-2) Strains in Japan (2020-2023): Evidence of Modified Live Vaccine Influence on Cluster Distribution.Epidemiologia (Basel, Switzerland) · 2025Article
- Genetics of reproductive performance across Porcine Reproductive and Respiratory Syndrome (PRRS) outbreak phases in purebred and crossbred sows.Genetics, selection, evolution : GSE · 2025Article
- Article
- Differential Effects of Selenium Compounds on Mitochondrial Function in PRRSV-Infected Porcine Alveolar Macrophages.Viruses · 2025Article
- Reduction in finisher pig death rate on a farm in Japan following use of a commercial killed vaccine against porcine reproductive and respiratory syndrome virus.The Journal of veterinary medical science · 2025Article
- Isolation and Biological Characteristics Study of Porcine Reproductive and Respiratory Syndrome Virus GZ2022 Strain.Veterinary sciences · 2025Article
- In Silico Designed Multi-Epitope Vaccine Based on the Conserved Fragments in Viral Proteins for Broad-Spectrum Protection Against Porcine Reproductive and Respiratory Syndrome Virus.Veterinary sciences · 2025Article
- Efficacy Evaluation of a VR-2332-Based Modified Live Vaccine Against NADC30-like PRRSV in China.Vaccines · 2025Article
- Immune Protection Gap Between Porcine Reproductive and Respiratory Syndrome Subunit Vaccine (N Protein) and Live Vaccine.Vaccines · 2025Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Porcine reproductive and respiratory syndrome (PRRS) virus (PRRSV) presents one of the challenging viral pathogens in the global pork industry. PRRS is characterized by two distinct clinical presentations; reproductive failure in breeding animals (gilts, sows, and boars), and respiratory disease in growing pigs. PRRSV is further divided into two species: PRRSV-1 (formerly known as the European genotype 1) and PRRSV-2 (formerly known as the North American genotype 2). A PRRSV-2 modified-live virus (MLV) vaccine was first introduced in North America in 1994, and, six years later, a PRRSV-1 MLV vaccine was also introduced in Europe. Since then, MLV vaccination is the principal strategy used to control PRRSV infection. Despite the fact that MLV vaccines have shown some efficacy, they were problematic as the efficacy of vaccine was often unpredictable and depended highly on the field virus. This paper focused on the efficacy of commercially available MLV vaccines at a global level based on respiratory disease in growing pigs, and maternal and paternal reproductive failure in breeding animals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.